Mumbai: Marksans Pharma Limited has announced that the company has received final approval from US Food & Drugs Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg.
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Lyrica Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg, of Upjohn US 2 LLC.
The medicine is indicated in relieving pain resulting from nerve damage because of diabetes, shingles, spinal cord injury, or other conditions.
Pregabalin capsules (RLD Lyrica) had estimated annual sales of USD 263 million in the U.S. (IQVIA MAT March 2022).
Read also: Marksans Pharma to acquire 100 percent stake in Access Healthcare for Rs 27 crore
Marksans Pharma, headquartered at Mumbai (India) is a global pharmaceutical company.
The company's key focus areas lie in the OTC & prescription drugs that have wide-ranging applications across fields like Oncology, Gastroenterology, Antidiabetic, Antibiotics, Cardiovascular, Pain Management, Gynaecology, among others.
Read also: Marksans Pharma gets UK MHRA nod for Bells Healthcare All in One Oral Solution
Ruchika joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Allergic rhinitis-an overview on treatment recommendations and current guidelines
A quick review on flu and the growing role of Oseltamivir
Opinion: New "Drugs, Medical Devices and Cosmetics Bill 2022" Can Be Made Robust
Infographic: Allergic Rhinitis-Quick Overview of Treatment Algorithm
Challenges in Rural Child Health: Experiences of a pediatrician in Rural Haryana- Dr Preeti Joon
Association of prior head injury with sense of smell in older adults